Sales to outside customers increased significantly to 19,163 million yen
(up 38.0% year-on-year).
Sales of the mainstay anti-inflammatory analgesic products decreased due
to timing discrepancies in shipments to the Middle East. However, Dax Cosmetics,
based in Poland, contributed to the increase in sales due to the strong
sales of "Perfecta" and "Hadalabo Tokyo," whose target
countries of sale have been expanded. In addition, the Company has been
developing the eye drop market since 2021 with "Rohto Dry Aid",
whose sales remained strong. Furthermore, Mono chem-pharm Produkte GmbH
has also contributed to sales.
Segment profit (operating income basis) increased to 1,425 million yen
(up 2.9% year-on-year) due to an increase in sales of Dax Cosmetics, which
offset a decrease in sales of the mainstay anti-inflammatory analgesic
products.